Melbourne (Australia) | 13 May 2025
Telix advises that it has evaluated the Executive Order issued by the United States (U.S.) Government[1] to implement a “Most-Favored Nation” (MFN) policy around drug pricing. Based on currently available information, there is a low likelihood of material impact to Telix’s business.
Due to their complex supply chain and just-in-time manufacturing requirements, radiopharmaceuticals differ from traditional pharmaceutical products. Telix’s U.S. pricing strategy reflects its focus on providing ready-to-inject radioactive doses delivered through locally-based nuclear pharmacy distributors. The localized production makes international pricing comparisons challenging to benchmark.
Telix currently generates the majority of its revenue from sales of Illuccix® in the U.S. and value in our U.S. market for access and pricing strategy, including U.S. government accounts, is a key focus for our business. Telix intends to commercialize its pipeline products TLX250-CDx (Zircaix®)[2] and TLX101-CDx (Pixclara®)[2] in the U.S. ahead of expansion into other global markets in turn setting effective and pharmaco-economically defensible pricing policies. Moreover, Telix continues to invest heavily in its U.S.-based manufacturing and distribution footprint to more quickly and cost-effectively bring these innovative and novel precision medicine products to U.S. patients.
Telix Managing Director and Group CEO, Dr. Christian Behrenbruch, said, “Radiopharmaceuticals represent a novel and emerging class of oncology treatments, driven by a precision medicine approach. We remain actively engaged with lawmakers, policymakers, and regulatory agencies to educate these stakeholders on the unique and complex nature of these innovative drugs. Telix is committed to supporting American healthcare policy that continues to advance care and promote broad patient access.”
[1] Delivering Most Favored-Nation Prescription Drug Pricing to American Patients, Executive Order, May 12, 2025, available at https://www.whitehouse.gov/presidential-actions/2025/05/delivering-most-favored-nation-prescription-drug-pricing-to-american-patients/
[2] TLX250-CDx and TLX101-CDx have not received a marketing authorization in any jurisdiction. Provisional brand names are subject to regulatory approval.